CLDN1 and ductal breast carcinoma in situ: No correlation could be found between loss of claudin-1 and clinical stage, TNM stage, sentinel lymph node status, adverse survival outcome, pathological complete response, DCIS presence, tumour size, right versus left breast, age and concurrent β-catenin expression.